“Duopharma’s ambitious and critical production expansions and associated costs are likely to weigh on operational cost in the near term. However, this would be more than offset by Duopharma’s expansion of products, which increases margin-enhancing non-insulin revenue, ” it said.
KUALA LUMPUR: UOB Kay Hian Malaysia Research maintained its Buy call on Duopharma
Biotech with a higher target price of RM1.77 from RM1.67 as it raised its earnings, pegged to 18 times FY20F price-to-earnings (PE).
The research house said on Tuesday Duopharma should be pegged to a higher premium to its local peers (13 times one-year forward).
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
